Wockhardt Limited
WOCKPHARMA
Kedudukan dalam Saham
#4551
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Harga Saham
$20.75
Modal Pasaran
$3.37B
Perubahan (1 hari)
-1.38%
Perubahan (1 tahun)
33.03%
Negara
IN
Perdagangan Wockhardt Limited (WOCKPHARMA)
Kategori
Healthcare
Hasil untuk Wockhardt Limited (WOCKPHARMA)
Hasil pada Jun 2026 TTM: $393.32M
Menurut laporan kewangan terkini daripada Wockhardt Limited, hasil semasa syarikat (TTM) ialah $393.32M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $339.40M peningkatan berbanding hasil pada tahun 2023 iaitu $323.31M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Wockhardt Limited dari 2004 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $393.32M | 10.84% |
| 2025 | $354.86M | 4.56% |
| 2024 | $339.40M | 4.97% |
| 2023 | $323.31M | -24.02% |
| 2022 | $425.51M | 15.02% |
| 2021 | $369.93M | -2.01% |
| 2020 | $377.51M | -26.48% |
| 2019 | $513.51M | -14.80% |
| 2018 | $602.74M | -1.45% |
| 2017 | $611.63M | -9.01% |
| 2016 | $672.19M | -6.41% |
| 2015 | $718.21M | -10.88% |
| 2014 | $805.87M | -22.17% |
| 2013 | $1.04B | 13.80% |
| 2012 | $909.89M | 8.10% |
| 2011 | $841.74M | -16.02% |
| 2010 | $1.00B | 35.33% |
| 2008 | $740.59M | 9.85% |
| 2007 | $674.18M | 72.85% |
| 2006 | $390.03M | 24.39% |
| 2005 | $313.56M | 9.96% |
| 2004 | $285.15M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $2.54B | 544.77% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | 111.23% |
US
|
